AACHEN & FRANKFURT, Germany--(BUSINESS WIRE)--The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) and ERGOMED Clinical Research Limited today announce data from the open-label Phase IIa study with the NMDA receptor antagonist CNS 5161 which was completed in December 2008. The final reported data confirm that the substance is safe and well-tolerated within the applied administration scheme which covered a large dose range. Adverse events were of mild and moderate intensity, relating mainly to the cardiovascular and the nervous system and were completely resolved following end of treatment. Importantly, none of the psychomimetic side effects normally associated with NMDA antagonist have been observed whilst signs of pain reduction were noted even at the second lowest dosing.
